文献速递淋巴瘤白血病

慢性淋巴细胞白血病与单克隆B淋巴细胞增多症患者的COVID-19疫苗失败:体液与细胞免疫

COVID-19 vaccine failure in chronic lymphocytic leukaemia and monoclonal B-lymphocytosis; humoural and cellular immunity.
PubMed 文献 · Br J Haematol · 2022-01-05

研究评估181例慢性淋巴细胞白血病(CLL,160例)与单克隆B淋巴细胞增多症(MBL,21例)患者接种两剂COVID-19疫苗后的体液与细胞免疫应答。第一剂后CLL与MBL分别有79.2%与50%保持血清阴性,第二剂后分别有45%与9.5%保持血清阴性。多因素分析显示IgM降低与活动性治疗与第二剂后抗体水平显著相关,约80%代表性样本T细胞应答正常。

要点

  • 第二剂后CLL患者45%、MBL患者9.5%仍血清阴性。
  • CLL患者72.9%、MBL患者53.3%未达到抗刺突蛋白≥1000 AU/ml。
  • 初治患者36.6%、治疗中78.1%、伊布替尼治疗中85.7%出现血清转化失败。

核心结论

  • CLL与MBL患者接种两剂COVID-19疫苗后血清转化失败率较高,CLL高于MBL,抗刺突蛋白水平低于正常供者。

研究设计与样本

  • 研究纳入181例患者,其中CLL 160例、MBL 21例,评估接种两剂疫苗后体液与细胞免疫应答,并将血清转化失败与临床及实验室参数进行相关分析。

主要发现

  • 第一剂后CLL 79.2%、MBL 50%保持血清阴性;第二剂后CLL 45%、MBL 9.5%保持血清阴性。
  • 单因素分析中第二剂后抗体水平与接种前IgM降低(p<0.0001)、IgG2降低(p<0.035)、IgG3降低(p<0.046)及12个月内CLL治疗(p<0.001)显著相关。
  • 多因素分析中IgM降低(p<0.0002)与活动性治疗(p<0.0002)保持显著。
  • 抗刺突蛋白水平在CLL低于MBL,两者均低于正常供者;抗刺突蛋白<1000 AU/ml时对早期病毒株与Delta变异株中和活性通常为阴性。
  • CLL 72.9%、MBL 53.3%未达到抗刺突蛋白≥1000 AU/ml;代表性样本中约80%T细胞应答正常。

关键数值与推荐

  • 血清转化失败定义为SARS-CoV-2 II IgG检测(抗刺突蛋白抗体,Abbott Diagnostics)<50 AU/ml。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic lymphocytic leukaemia (CLL) is associated with immunocompromise and high risk of severe COVID-19 disease and mortality. Monoclonal B-cell lymphocytosis (MBL) patients also have immune impairment. We evaluated humoural and cellular immune responses in 181 patients with CLL (160) and MBL (21) to correlate failed seroconversion [<50 AU/ml SARS-CoV-2 II IgG assay, antibody to spike protein; Abbott Diagnostics)] following each of two vaccine doses with clinical and laboratory parameters. Following first and second doses, 79.2% then 45% of CLL, and 50% then 9.5% of MBL patients respectively remained seronegative. There was significant association between post dose two antibody level with pre-vaccination reduced IgM (p < 0.0001), IgG2 (p < 0.035), and IgG3 (p < 0.046), and CLL therapy within 12 months (p < 0.001) in univariate analysis. By multivariate analysis, reduced IgM (p < 0.0002) and active therapy (p < 0.0002) retained significance. Anti-spike protein levels varied widely and were lower in CLL than MBL patients, and both lower than in normal donors. Neutralisation activity showed anti-spike levels <1000 AU/ml were usually negative for both an early viral clade and the contemporary Delta variant and 72.9% of CLL and 53.3% of MBL failed to reach levels ≥1000 AU/ml. In a representative sample, ~80% had normal T-cell responses. Failed seroconversion occurred in 36.6% of treatment-naïve patients, in 78.1% on therapy, and in 85.7% on ibrutinib.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Shen Y, Freeman JA, Holland J, et al. COVID-19 vaccine failure in chronic lymphocytic leukaemia and monoclonal B-lymphocytosis; humoural and cellular immunity. Br J Haematol. 2022. PMID: 34962656. doi:10.1111/bjh.18014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。